feed,title,long_url,short_url
BioRxiv,Differential laboratory passaging of SARS-CoV-2 viral stocks impacts the in vitro assessment of neutralizing antibodies,https://biorxiv.org/cgi/content/short/2023.07.14.549044v1?rss=1,https://da.gd/LM8c
BioRxiv,Nanobody repertoire generated against the spike protein of ancestral SARS-CoV-2 remains efficacious against the rapidly evolving virus,https://biorxiv.org/cgi/content/short/2023.07.14.549041v1?rss=1,https://da.gd/fexNH
